Form 4: Clene Inc. Director Jonathon Gay Granted Stock Options

Director Jonathon Gay received stock options for 37,957 shares of Clene Inc. common stock on March 11, 2024.

Summary

• On March 11, 2024, Jonathon Gay, a director of Clene Inc., was granted stock options to purchase 37,957 shares of the company's common stock.
• The exercise price for these options is $0.44 per share.
• The options were granted under the Clene Inc. Amended 2020 Stock Plan and vest immediately.
• The options expire on March 11, 2034.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing related to stock option grants, which is generally neutral in sentiment. It reflects standard compensation practices.

Positives

• The immediate vesting of the options could incentivize the director to work towards the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize directors and key employees.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their compensation strategy to align the interests of management with those of shareholders.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• It may incentivize the director to act in the best interests of the company, which could benefit all stakeholders.

Key Dates